Medical Advocates
Amprenavir (Agenerase)
 
Pediatric Data


Safety
 Pharmacokinetics
 Adverse Events
 Efficacy


 

 
Amprenavir Main Page Main New/Newsworthy  Home Page
Last Update:  February 17, 2015
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
Safety
 
Journal Papers, Abstracts, and Commentaries
 
  Safety profile and tolerability of amprenavir in the treatment of adult and pediatric patients
with HIV infection.
Pedneault L, Brothers C, Pagano G, et al.
Clin Ther 2000  Dec;22(12):1378-94; discussion 1377
Abstract
Pharmacokinetics
 

Journal Papers, Abstracts, and Commentaries

 

Pharmacokinetic and pharmacodynamic analysis of amprenavir-containing combination
therapy in HIV-1-infected children.
Stein DS, Lou Y, Johnson M, et al 
J Clin Pharmacol. 2004 Nov;44(11):1301-8.
 Abstract

Pharmacokinetic and Pharmacodynamic Analysis of Amprenavir-Containing Combination
Therapy n HIV-1-Infected Children.
Stein DS, Lou Y, Johnson M,et al 
J Clin Pharmacol. 2004 Nov;44(11):1301-8
 Abstract
Adverse Events
 

Journal Papers, Abstracts, and Commentaries

  Relationship of prolonged pharmacologic serum levels of vitamin E to incidence of sepsis and
necrotizing enterocolitis in infants with birth weight 1,500 grams or less.  
Johnson L, Bowen FW, Jr., Abbasi S et al.
Pediatrics 1985; 75(4): 619-638.
Abstract
Efficacy
 

Journal Papers, Abstracts, and Commentaries
 
Single-Dose Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency
Virus Type 1 (HIV-1) Protease Inhibitor, in HIV-Infected Children.
Yogev R, Kovacs A, Chadwick EG ,et al  
Antimicrob Agents Chemother. 2005 Jan;49(1):336-41.
 Abstract

A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and
zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus
type 1-infected children.
Saez-Llorens X, Nelson RP, Emmanuel P et al
Pediatrics. 2001 Jan;107(1):E4
 Abstract

Conference Reports, Abstracts, and Posters 

  Pediatric trial of combination therapy including the protease inhibitor amprenavir (APV).
 Yogev R, Church J, Flynn P et al.
 (6RETRO)
Abstract

 
Amprenavir Main Page Main New/Newsworthy  Home Page

Amprenavir Pediatric Data